Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Naotake Funamizu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6076-6516; OpenAlex author ID A5059857750. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 16

  1. Microbiome Disturbance, Nutritional Vulnerability, and Treatment Tolerance in Pancreatic Ductal Adenocarcinoma: Mechanistic Links and Clinical Readiness. Co-author DOI 10.3390/cancers18162658↗
  2. Novel modified frailty index predicts completion of adjuvant chemotherapy in resectable pancreatic cancer in a dual center study. Co-author DOI 10.1038/s41598-025-02365-5↗
  3. Long-term survival in a patient with postoperative pulmonary oligometastasis of pancreatic cancer treated with surgical resection and chemotherapy: A case repo… Co-author DOI 10.1097/md.0000000000043647↗
  4. Postoperative Geriatric Nutritional Risk Index as a Determinant of Tolerance to S-1 Adjuvant Chemotherapy After Curative Surgery for Pancreatic Ductal Adenocar… Co-author DOI 10.3390/cancers17091448↗
  5. Nutritional Status and Chemotherapy Completion in Resectable Pancreatic Cancer: A Narrative Review. Co-author DOI 10.3390/curroncol32090519↗
  6. Refractory postoperative pancreatic fistula following laparoscopic distal pancreatectomy for pancreatic cancer caused by incomplete pancreas divisum: a case re… Co-author DOI 10.1007/s12328-024-01942-x↗
  7. C-Reactive Protein-to-Albumin Ratio to Predict Tolerability of S-1 as an Adjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16050922↗
  8. C-Reactive Protein-to-Albumin Ratio as a Predictive Indicator for Evaluating Tolerability in S-1 Adjuvant Chemotherapy after Curative Surgery for Pancreatic Ca… Co-author DOI 10.3390/cancers16193372↗
  9. Geriatric Nutritional Risk Index Predicts Tolerability of S-1 as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002240↗
  10. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. Co-author DOI 10.3390/cancers15041230↗
  11. Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study. Co-author DOI 10.1038/s41598-022-18077-z↗
  12. A case of radical resection for brain metastases of pancreatic cancer after curative chemotherapy for para-aortic lymph node metastases. First author DOI 10.1186/s40792-022-01461-2↗
  13. Association between the Preoperative C-Reactive Protein-to-Albumin Ratio and the Risk for Postoperative Pancreatic Fistula following Distal Pancreatectomy for … Co-author DOI 10.3390/nu14245277↗
  14. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  15. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗
  16. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0031507↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutsugu Takada · 10 shared papers, 2022–2025 · strength 1.91
  2. Yuzo Umeda · 6 shared papers, 2024–2026 · strength 1.62
  3. Akimasa Sakamoto · 8 shared papers, 2022–2025 · strength 1.59
  4. Taku Aoki · 3 shared papers, 2024–2025 · strength 0.66
  5. Takeshi Utsunomiya · 2 shared papers, 2022 · strength 0.29
  6. Tsunemichi Hirose · 1 shared paper, 2025 · strength 0.28
  7. Mitsuhito Koizumi · 1 shared paper, 2024 · strength 0.24
  8. Yuki Numata · 1 shared paper, 2024 · strength 0.24
  9. Nader N Hanna · 3 shared papers, 2012–2016 · strength 0.10
  10. Β. Michael Ghadimi · 3 shared papers, 2012–2016 · strength 0.10
  11. Jochen Gaedcke · 3 shared papers, 2012–2016 · strength 0.10
  12. H. Richard Alexander · 3 shared papers, 2012–2016 · strength 0.10
  13. S. Perwez Hussain · 3 shared papers, 2012–2016 · strength 0.10
  14. Katsuhiko K. Yanaga · 2 shared papers, 2013–2016 · strength 0.07
  15. Geng Zhang · 2 shared papers, 2012–2013 · strength 0.05
  16. Anirban Maitra · 2 shared papers, 2012–2013 · strength 0.05
  17. Shouhui Yang · 1 shared paper, 2016 · strength 0.05
  18. Jian Wang · 1 shared paper, 2016 · strength 0.05
  19. Matthias M. Gaida · 1 shared paper, 2016 · strength 0.05
  20. Tadashi Uwagawa · 1 shared paper, 2016 · strength 0.05
  21. Jens Werner · 1 shared paper, 2016 · strength 0.05
  22. Michael B. Ghadimi · 1 shared paper, 2013 · strength 0.03
  23. Dong Ho Lee · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.